超声引导下针刀疗法辅助射频消融术治疗神经根型颈椎病的临床观察OA北大核心CSTPCDMEDLINE

Objective To observe the clinical efficacy and safety of ultrasound-guided acupotomy in adjuvant treatment of residual symptoms after percutaneous cervical disc nucleoplasty(PCDN)for cervical spondylotic radiculopathy(CSR).Methods A total of 70 CSR patients were divided into treatment group and control group according to random number table,with 35 cases in each group.Patients in the control group received PCDN,while patients in the treatment group further received ultrasound-guided acupotomy,which was performed once every 5 to 7 days for a total of 4 to 6 times(adjusted according to the condition of patients).The visual analog score(VAS),neck dysfunction index(NDI),Japanese Orthopaedic Association cervical spondylosis scale(JOA score),and Tanaka Yasuhisa 20-point scale were adopted in the assessment before PCDN and 1 day,1 month,3 months,6 months after PCDN.The clinical efficacy,postoperative adverse reactions and complications of the 2 groups were evaluated.Results Compared with those before PCDN,the VAS score and NDI score of the 2 groups were decreased(P<0.05),JOA score and Tanaka Yasuhisa 20-point score were increased(P<0.05)at 1 day and 1,3 and 6 months after surgery.Compared with same group 1 day after surgery,the VAS score and NDI score of the treatment group were decreased(P<0.05),while JOA score and Tanaka Yasuhisa 20-point score were increased(P<0.05)at 1,3 and 6 months after surgery.Compared with the control group at the same time points,the VAS score and NDI score of the treatment group were decreased(P<0.05),while JOA score and Tanaka Yasuhisa 20-point score were increased(P<0.05)at 1,3 and 6 months after operation.The effective rate and excellent rate of the treatment group 1,3 and 6 months after PCDN were higher than those of the control group(P<0.05).Follow-up to 1 year after surgery,no significant postoperative adverse reactions and complications were found in both groups.Conclusion Ultrasound-guided acupotomy can significantly improve the residual symptoms after PCDN for CSR patients,and the clinical efficacy is significantly better than that of PCDN alone,and this therapy is safe and reliable.